TP53 mutations and del (17p) are among the most common adverse prognostic factors in CLL/SLL, closely associated with accelerated disease progression, increased treatment resistance, and shorter PFS. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.